TY - JOUR AU - Slamon, D. J. AU - Godolphin, W. AU - Jones, L. A. AU - Holt, J. A. AU - Wong, S. G. AU - Keith, D. E. AU - Levin, W. AU - Stuart, S. AU - Udove, J. AU - Ullrich, A. PY - 1989 DA - 1989// TI - Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer JO - Science. VL - 244 UR - https://doi.org/10.1126/science.2470152 DO - 10.1126/science.2470152 ID - Slamon1989 ER - TY - JOUR AU - Ocaña, A. AU - Pandiella, A. PY - 2013 DA - 2013// TI - Targeting HER receptors in cancer JO - Curr Pharm Des VL - 19 UR - https://doi.org/10.2174/138161213804547303 DO - 10.2174/138161213804547303 ID - Ocaña2013 ER - TY - JOUR AU - García-Alonso, S. AU - Ocaña, A. AU - Pandiella, A. PY - 2020 DA - 2020// TI - Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond JO - Trends Cancer VL - 6 UR - https://doi.org/10.1016/j.trecan.2019.12.010 DO - 10.1016/j.trecan.2019.12.010 ID - García-Alonso2020 ER - TY - JOUR AU - Shu, S. AU - Polyak, K. PY - 2016 DA - 2016// TI - BET bromodomain proteins as cancer therapeutic targets JO - Cold Spring Harb Symp Quant Biol VL - 81 UR - https://doi.org/10.1101/sqb.2016.81.030908 DO - 10.1101/sqb.2016.81.030908 ID - Shu2016 ER - TY - STD TI - Khandekar D, Tiriveedhi V. Role of BET inhibitors in triple negative breast cancers. Cancers. 2020;12(4). https://doi.org/10.3390/cancers12040784. ID - ref5 ER - TY - JOUR AU - Ocaña, A. AU - Nieto-Jiménez, C. AU - Pandiella, A. PY - 2017 DA - 2017// TI - BET inhibitors as novel therapeutic agents in breast cancer JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.19744 DO - 10.18632/oncotarget.19744 ID - Ocaña2017 ER - TY - JOUR AU - Pérez-Salvia, M. AU - Esteller, M. PY - 2017 DA - 2017// TI - Bromodomain inhibitors and cancer therapy: from structures to applications JO - Epigenetics VL - 12 UR - https://doi.org/10.1080/15592294.2016.1265710 DO - 10.1080/15592294.2016.1265710 ID - Pérez-Salvia2017 ER - TY - JOUR AU - Khan, S. AU - He, Y. AU - Zhang, X. AU - Yuan, Y. AU - Pu, S. AU - Kong, Q. AU - Zheng, G. AU - Zhou, D. PY - 2020 DA - 2020// TI - PROteolysis TArgeting chimeras (PROTACs) as emerging anticancer therapeutics JO - Oncogene. VL - 39 UR - https://doi.org/10.1038/s41388-020-1336-y DO - 10.1038/s41388-020-1336-y ID - Khan2020 ER - TY - JOUR AU - Ocaña, A. AU - Pandiella, A. PY - 2020 DA - 2020// TI - Proteolysis targeting chimeras (PROTACs) in cancer therapy JO - J Exp Clin Cancer Res CR VL - 39 UR - https://doi.org/10.1186/s13046-020-01672-1 DO - 10.1186/s13046-020-01672-1 ID - Ocaña2020 ER - TY - JOUR AU - Zengerle, M. AU - Chan, K. -. H. AU - Ciulli, A. PY - 2015 DA - 2015// TI - Selective small molecule induced degradation of the BET bromodomain protein BRD4 JO - ACS Chem Biol VL - 10 UR - https://doi.org/10.1021/acschembio.5b00216 DO - 10.1021/acschembio.5b00216 ID - Zengerle2015 ER - TY - JOUR AU - Sun, B. AU - Fiskus, W. AU - Qian, Y. AU - Rajapakshe, K. AU - Raina, K. AU - Coleman, K. G. AU - Crew, A. P. AU - Shen, A. AU - Saenz, D. T. AU - Mill, C. P. AU - Nowak, A. J. AU - Jain, N. AU - Zhang, L. AU - Wang, M. AU - Khoury, J. D. AU - Coarfa, C. AU - Crews, C. M. AU - Bhalla, K. N. PY - 2018 DA - 2018// TI - BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells JO - Leukemia. VL - 32 UR - https://doi.org/10.1038/leu.2017.207 DO - 10.1038/leu.2017.207 ID - Sun2018 ER - TY - JOUR AU - Noblejas-López, M. D. M. AU - Nieto-Jimenez, C. AU - Burgos, M. AU - Gómez-Juárez, M. AU - Montero, J. C. AU - Esparís-Ogando, A. PY - 2019 DA - 2019// TI - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer JO - J Exp Clin Cancer Res CR VL - 38 UR - https://doi.org/10.1186/s13046-019-1387-5 DO - 10.1186/s13046-019-1387-5 ID - Noblejas-López2019 ER - TY - JOUR AU - Corrales-Sánchez, V. AU - Noblejas-López, M. D. M. AU - Nieto-Jiménez, C. AU - Pérez-Peña, J. AU - Montero, J. C. AU - Burgos, M. PY - 2020 DA - 2020// TI - Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer JO - J Cell Mol Med VL - 24 UR - https://doi.org/10.1111/jcmm.14980 DO - 10.1111/jcmm.14980 ID - Corrales-Sánchez2020 ER - TY - JOUR AU - Alcaraz-Sanabria, A. AU - Nieto-Jiménez, C. AU - Corrales-Sánchez, V. AU - Serrano-Oviedo, L. AU - Andrés-Pretel, F. AU - Montero, J. C. AU - Burgos, M. AU - Llopis, J. AU - Galán-Moya, E. M. AU - Pandiella, A. AU - Ocaña, A. PY - 2017 DA - 2017// TI - Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-17-0223 DO - 10.1158/1535-7163.MCT-17-0223 ID - Alcaraz-Sanabria2017 ER - TY - JOUR AU - Gandullo-Sánchez, L. AU - Capone, E. AU - Ocaña, A. AU - Iacobelli, S. AU - Sala, G. AU - Pandiella, A. PY - 2020 DA - 2020// TI - HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies JO - EMBO Mol Med VL - 12 UR - https://doi.org/10.15252/emmm.201911498 DO - 10.15252/emmm.201911498 ID - Gandullo-Sánchez2020 ER - TY - STD TI - Pertuzumab and Trastuzumab: the rationale way to synergy - PubMed. [cited 2020 Jul 3]. Available from: https://pubmed.ncbi.nlm.nih.gov/27275646/ UR - https://pubmed.ncbi.nlm.nih.gov/27275646/ ID - ref16 ER - TY - JOUR AU - Segovia-Mendoza, M. AU - González-González, M. E. AU - Barrera, D. AU - Díaz, L. AU - García-Becerra, R. PY - 2015 DA - 2015// TI - Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence JO - Am J Cancer Res VL - 5 ID - Segovia-Mendoza2015 ER - TY - JOUR AU - Gianni, L. AU - Eiermann, W. AU - Semiglazov, V. AU - Manikhas, A. AU - Lluch, A. AU - Tjulandin, S. PY - 2010 DA - 2010// TI - Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort JO - Lancet Lond Engl VL - 375 UR - https://doi.org/10.1016/S0140-6736(09)61964-4 DO - 10.1016/S0140-6736(09)61964-4 ID - Gianni2010 ER - TY - JOUR AU - Díaz-Rodríguez, E. AU - Pérez-Peña, J. AU - Ríos-Luci, C. AU - Arribas, J. AU - Ocaña, A. AU - Pandiella, A. PY - 2019 DA - 2019// TI - TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells JO - Cancer Lett VL - 453 UR - https://doi.org/10.1016/j.canlet.2019.03.042 DO - 10.1016/j.canlet.2019.03.042 ID - Díaz-Rodríguez2019 ER - TY - JOUR AU - Ocana, A. AU - Gil-Martin, M. AU - Antolín, S. AU - Atienza, M. AU - Montaño, Á. AU - Ribelles, N. AU - Urruticoechea, A. AU - Falcón, A. AU - Pernas, S. AU - Orlando, J. AU - Montero, J. C. AU - Escudero, M. J. AU - Benito, S. AU - Caballero, R. AU - Carrasco, E. AU - Rojo, F. AU - Pandiella, A. AU - Ruiz-Borrego, M. PY - 2019 DA - 2019// TI - Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study JO - Breast Cancer Res Treat VL - 174 UR - https://doi.org/10.1007/s10549-018-05100-z DO - 10.1007/s10549-018-05100-z ID - Ocana2019 ER - TY - STD TI - Pérez-Pena J, Páez R, Nieto-Jiménez C, Sánchez VC, Galan-Moya EM, Pandiella A, et al. Mapping Bromodomains in breast cancer and association with clinical outcome. Sci Rep. 2019;9 [cited 2020 Jul 21]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450889/. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450889/ ID - ref21 ER - TY - JOUR AU - Ciocan-Cartita, C. A. AU - Jurj, A. AU - Zanoaga, O. AU - Cojocneanu, R. AU - Pop, L. -. A. AU - Moldovan, A. AU - Moldovan, C. AU - Zimta, A. A. AU - Raduly, L. AU - Pop-Bica, C. AU - Buse, M. AU - Budisan, L. AU - Virag, P. AU - Irimie, A. AU - Gomes Dias, S. M. AU - Berindan-Neagoe, I. AU - Braicu, C. PY - 2020 DA - 2020// TI - New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells JO - J Exp Clin Cancer Res CR VL - 39 UR - https://doi.org/10.1186/s13046-020-01736-2 DO - 10.1186/s13046-020-01736-2 ID - Ciocan-Cartita2020 ER - TY - JOUR AU - Kreutzfeldt, J. AU - Rozeboom, B. AU - Dey, N. AU - De, P. PY - 2020 DA - 2020// TI - The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies JO - Am J Cancer Res VL - 10 ID - Kreutzfeldt2020 ER - TY - JOUR AU - Hughes, S. J. AU - Ciulli, A. PY - 2017 DA - 2017// TI - Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders JO - Essays Biochem VL - 61 UR - https://doi.org/10.1042/EBC20170041 DO - 10.1042/EBC20170041 ID - Hughes2017 ER - TY - JOUR AU - Stratikopoulos, E. E. AU - Dendy, M. AU - Szabolcs, M. AU - Khaykin, A. J. AU - Lefebvre, C. AU - Zhou, M. -. M. AU - Parsons, R. PY - 2015 DA - 2015// TI - Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy JO - Cancer Cell VL - 27 UR - https://doi.org/10.1016/j.ccell.2015.05.006 DO - 10.1016/j.ccell.2015.05.006 ID - Stratikopoulos2015 ER - TY - JOUR AU - Marivin, A. AU - Berthelet, J. AU - Plenchette, S. AU - Dubrez, L. PY - 2012 DA - 2012// TI - The Inhibitor of Apoptosis (IAPs) in adaptive response to cellular stress JO - Cells VL - 1 UR - https://doi.org/10.3390/cells1040711 DO - 10.3390/cells1040711 ID - Marivin2012 ER - TY - JOUR AU - Rothkamm, K. AU - Barnard, S. AU - Moquet, J. AU - Ellender, M. AU - Rana, Z. AU - Burdak-Rothkamm, S. PY - 2015 DA - 2015// TI - DNA damage foci: meaning and significance JO - Environ Mol Mutagen VL - 56 UR - https://doi.org/10.1002/em.21944 DO - 10.1002/em.21944 ID - Rothkamm2015 ER - TY - JOUR AU - Shi, J. AU - Vakoc, C. R. PY - 2014 DA - 2014// TI - The mechanisms behind the therapeutic activity of BET bromodomain inhibition JO - Mol Cell VL - 54 UR - https://doi.org/10.1016/j.molcel.2014.05.016 DO - 10.1016/j.molcel.2014.05.016 ID - Shi2014 ER - TY - JOUR AU - Errico, M. C. AU - Jin, K. AU - Sukumar, S. AU - Carè, A. PY - 2016 DA - 2016// TI - The widening sphere of influence of HOXB7 in solid tumors JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-15-3444 DO - 10.1158/0008-5472.CAN-15-3444 ID - Errico2016 ER - TY - JOUR AU - Rubin, E. AU - Wu, X. AU - Zhu, T. AU - Cheung, J. C. Y. AU - Chen, H. AU - Lorincz, A. AU - Pandita, R. K. AU - Sharma, G. G. AU - Ha, H. C. AU - Gasson, J. AU - Hanakahi, L. A. AU - Pandita, T. K. AU - Sukumar, S. PY - 2007 DA - 2007// TI - A role for the HOXB7 homeodomain protein in DNA repair JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-4283 DO - 10.1158/0008-5472.CAN-06-4283 ID - Rubin2007 ER - TY - JOUR AU - Tapia-Carrillo, D. AU - Tovar, H. AU - Velazquez-Caldelas, T. E. AU - Hernandez-Lemus, E. PY - 2019 DA - 2019// TI - Master regulators of signaling pathways: an application to the analysis of gene regulation in breast cancer JO - Front Genet VL - 10 UR - https://doi.org/10.3389/fgene.2019.01180 DO - 10.3389/fgene.2019.01180 ID - Tapia-Carrillo2019 ER - TY - JOUR AU - Montes, M. AU - Cloutier, A. AU - Sánchez-Hernández, N. AU - Michelle, L. AU - Lemieux, B. AU - Blanchette, M. PY - 2012 DA - 2012// TI - TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription JO - Mol Cell Biol VL - 32 UR - https://doi.org/10.1128/MCB.06255-11 DO - 10.1128/MCB.06255-11 ID - Montes2012 ER - TY - JOUR AU - Aloia, L. AU - Demajo, S. AU - Croce, L. D. PY - 2015 DA - 2015// TI - ZRF1: a novel epigenetic regulator of stem cell identity and cancer JO - Cell Cycle VL - 14 UR - https://doi.org/10.4161/15384101.2014.988022 DO - 10.4161/15384101.2014.988022 ID - Aloia2015 ER -